Granulocyte colony stimulating factor: A potential therapeutic rescue in severe alcoholic hepatitis and decompensated cirrhosis.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Fundación Clínica Médica Sur Country of Publication: Mexico NLM ID: 101155885 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1665-2681 (Print) Linking ISSN: 16652681 NLM ISO Abbreviation: Ann Hepatol Subsets: MEDLINE
    • Publication Information:
      Publication: 2011- : México : Fundación Clínica Médica Sur
      Original Publication: México : Ediciones Medicina y Cultura, 2002-
    • Subject Terms:
      Stem Cell Transplantation*; Granulocyte Colony-Stimulating Factor/*therapeutic use ; Hepatitis, Alcoholic/*therapy ; Liver Cirrhosis/*therapy; Humans
    • Abstract:
      Liver cirrhosis accounts for over 2 million deaths annually worldwide. A subset of these patients - those with alcoholic hepatitis and decompensated cirrhosis, have abysmal short-term survival. Liver transplant is the only intervention of proven survival benefit; however organ availability is a major limitation. It is thus imperative to assess potential benefit of experimental therapies as a bridge to transplant. Stem cell therapies have shown some promise in patients with end-stage liver disease. Of these, bone-marrow derived hematopoietic stem cells have generated the most interest. Animal as well as human data suggest biological plausibility of stem cell translocation from bone marrow to liver, giving credence to cytokine therapies based on bone marrow stimulation. Granulocyte colony stimulating factor has been the most frequently used cytokine for this purpose. This intervention has shown encouraging results in terms of safety as well as survival benefits in small clinical trials. The evidence, however, is sparse and heterogeneous. In this review we describe the biological plausibility, mechanisms of action, and clinical evidence of the use of cytokine based stem cell therapy in patients with end-stage liver disease.
      (Copyright © 2020 Fundación Clínica Médica Sur, A.C. Published by Elsevier España, S.L.U. All rights reserved.)
    • Contributed Indexing:
      Keywords: Alcoholic hepatitis; Cirrhosis; Decompensated cirrhosis; GCSF; Refractory ascites
    • Accession Number:
      143011-72-7 (Granulocyte Colony-Stimulating Factor)
    • Publication Date:
      Date Created: 20200614 Date Completed: 20211028 Latest Revision: 20211028
    • Publication Date:
      20250114
    • Accession Number:
      10.1016/j.aohep.2020.04.011
    • Accession Number:
      32533952